ABL1 V299L

CI-VAR-00004516Explore in graph →NP_005148.2:p.Val299LeuNM_005157.5:c.895G>CCIViC 4639 rs1057519771

Curated evidence

Evidence by cancer (15 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–15 of 15 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive15
BCR::ABL1 Fusion AND ABL1 E255K AND ABL1 V299L	Dasatinib + PonatinibSubstitutes	Predictive	D	Supports Sensitivity Response	2	accepted	EID7781 Bone marrow mononuclear cells isolated from a chronic myeloid leukemia patient with the BCR-ABL1 fusion and E255K and V299L secondary variants in ABL1 showed a high drug sensitivity score to ponatinib… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 E255V AND ABL1 V299L	Axitinib	Predictive	D	Supports Resistance	2	submitted	EID12314 In an in vitro study, pro-B Ba/F3 cell line expressing a compound mutant of both E255V and V299L mutations in the ABL1 portion of the BCR-ABL1 fusion protein demonstrated resistance to axitinib treatm… (full text at CIViC) PMID 26582647 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.